Media stories about Regeneron Pharmaceuticals (NASDAQ:REGN) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.515199380995 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- $1.54 Billion in Sales Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter (americanbankingnews.com)
- Alnylam and Regeneron team up in NASH – Seeking Alpha (seekingalpha.com)
- Regeneron Is Still In a Downtrend – TheStreet.com (realmoney.thestreet.com)
- Regeneron (REGN) Genetics Center Publication in NEJM Identifies New Genetic Variant Providing Protection from Chronic Liver Disease (streetinsider.com)
- Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead? (finance.yahoo.com)
A number of analysts have commented on the stock. BTIG Research reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 13th. Deutsche Bank set a $367.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, March 13th. ValuEngine lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. Canaccord Genuity lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price objective for the company from $522.00 to $356.00 in a report on Wednesday, February 21st. Finally, Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $380.00 price objective on the stock in a report on Friday, February 16th. Four research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $449.49.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same quarter in the prior year, the business posted $3.04 EPS. The firm’s revenue was up 28.9% compared to the same quarter last year. sell-side analysts predict that Regeneron Pharmaceuticals will post 19.2 earnings per share for the current fiscal year.
In related news, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total value of $325,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Joseph L. Goldstein sold 2,000 shares of the company’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $350.02, for a total transaction of $700,040.00. Following the completion of the sale, the director now owns 14,000 shares in the company, valued at approximately $4,900,280. The disclosure for this sale can be found here. Insiders sold a total of 5,000 shares of company stock worth $1,705,640 in the last 90 days. 10.80% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3303156/regeneron-pharmaceuticals-regn-earning-somewhat-positive-press-coverage-report-finds.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
